"Celebrex 200mg low price, rheumatoid arthritis definition nhs."

By: Amy Garlin MD

• Associate Clinical Professor

https://publichealth.berkeley.edu/people/amy-garlin/

If required by the Corporation arthritis lumps generic 200 mg celebrex, certificates surrendered for conversion shall be endorsed or accompanied by a written instrument or instruments of transfer rheumatoid arthritis mechanism discount celebrex 200 mg line, in form satisfactory to the Corporation, duly executed by the registered holder or his, her or its attorney duly authorized in writing. Please Consider the Environment Before Printing this Document agent) of such certificate or certificates (or lost certificate affidavit and agreement) and the Conversion Notice shall be the time of conversion (the Conversion Time), and the shares of Common Stock issuable upon conversion of the shares represented by such certificate or certificates shall be deemed to be outstanding of record as of such date. The Corporation shall, as soon as practicable after the Conversion Time, (i) issue and deliver to such holder of Preferred Stock, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock issuable upon such conversion in accordance with the provisions hereof and a new certificate for the number of shares, if any, of Preferred Stock represented by the surrendered certificate or certificates that were not converted into Common Stock, (ii) pay in cash such amount as provided in Subsection 4. The Corporation shall at all times when Preferred Stock shall be outstanding reserve and keep available out of its authorized but unissued capital stock, for the purpose of effecting the conversion of Preferred Stock (including any conversion pursuant to Section 4 or Section 5), such number of its duly authorized shares of Common Stock as shall from time to time be sufficient to effect the conversion of all then outstanding shares of Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding shares of Preferred Stock, the Corporation shall take such corporate action as may be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes. Before taking any action that would cause an adjustment reducing any Conversion Price below the then par value of the shares of Common Stock issuable upon conversion of Preferred Stock, the Corporation shall take any corporate action which may, in the opinion of its counsel, be necessary in order that the Corporation may validly and legally issue fully paid and nonassessable shares of Common Stock at such adjusted Conversion Price. All shares of Preferred Stock which shall have been surrendered for conversion as provided in this Section 4 shall no longer be deemed to be outstanding and all rights with respect to such shares shall immediately cease and terminate at the Conversion Time, except only the right of the holders thereof to receive the items provided for in the last sentence of Subsection 4. Any shares of Preferred Stock so converted shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of Preferred Stock accordingly. Upon any such conversion, no adjustment to the Conversion Price shall be made for any declared but unpaid dividends on the relevant series of Preferred Stock surrendered for conversion or on Common Stock delivered upon conversion. The Corporation shall pay any and all issue and other similar taxes that may be payable in respect of any issuance or delivery of shares of Common Stock upon conversion of shares of Preferred Stock pursuant to this Section 4. The Corporation shall not, however, be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of shares of Common Stock in a name other than that in which the shares of Preferred Stock so converted were registered, and no such issuance or delivery shall be made unless and until the person or entity requesting such issuance has paid to the Corporation the amount of any such tax or has established, to the satisfaction of the Corporation, that such tax has been paid. Notwithstanding anything herein to the contrary, no adjustment of the Conversion Price with respect to any series of Preferred Stock shall be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the holders of a majority of the then outstanding shares of Preferred Stock, with all series voting together as a single class, agreeing that no such adjustment shall be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock; provided, however, that the waiver of any adjustment of the Conversion Price applicable to the Series B Preferred Stock shall require the consent of the holders of a majority of the shares of Series B Preferred Stock then outstanding. Notwithstanding the foregoing, no readjustment pursuant to this clause (b) shall have the effect of increasing the relevant Conversion Price to an amount which exceeds the lower of (1) the relevant Conversion Price in effect immediately prior to the original adjustment made as a result of the issuance of such Option or Convertible Security (or the occurrence of a record date with respect thereto) or (2) the Conversion Price that would have resulted from any issuances of Additional Shares of Common Stock (other than deemed issuances of Additional Shares of Common Stock as a result of the issuance of such Option or Convertible Security) between the original adjustment date and such readjustment date. Please Consider the Environment Before Printing this Document (c) If the terms of any Option or Convertible Security (excluding Options or Convertible Securities which are themselves Exempted Securities), the issuance of which did not result in an adjustment to any Conversion Price pursuant to the terms of Subsection 4. If, at any time after the applicable Original Series B Issue Date, the Corporation issues Additional Shares of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant to Subsection 4. Please Consider the Environment Before Printing this Document (b) Options and Convertible Securities. Such consideration shall, in the event that Additional Shares of Common Stock are deemed to have been issued pursuant to Subsection 4. If the Corporation issues, on more than one date, Additional Shares of Common Stock that are a part of one transaction or a series of related transactions and that would result in an adjustment to any Conversion Price pursuant to the terms of Subsection 4. If the Corporation at any time or from time to time after the Original Series B Issue Date effects a subdivision of the outstanding shares of Common Stock into a greater number of shares of Common Stock, the relevant Conversion Price in effect immediately before the subdivision shall be proportionately decreased so that the number of shares of Common Stock issuable on conversion of each share of such series shall be increased in proportion to such increase in the aggregate number of shares of Common Stock outstanding. Please Consider the Environment Before Printing this Document number of shares of Common Stock, the relevant Conversion Price in effect immediately before the combination shall be proportionately increased so that the number of shares of Common Stock issuable on conversion of each share of such series shall be decreased in proportion to such decrease in the aggregate number of shares of Common Stock outstanding. The relevant Conversion Price shall be readjusted in the same manner upon the happening of each subsequent subdivision or combination of the outstanding shares of Common Stock. If the Corporation at any time or from time to time after the Original Series B Issue Date makes or issues, or fixes a record date for the determination of holders of Common Stock entitled to receive, a Common Stock Dividend, then in each such event the relevant Conversion Price in effect immediately before such event shall be decreased as of the time of such issuance or, in the event such a record date shall have been fixed, as of the close of business on such record date, by multiplying the such Conversion Price then in effect by a fraction: (1) the numerator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date; and (2) the denominator of which shall be the sum of (a) the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date and (b) the total number of shares of Common Stock issuable in payment of such Common Stock Dividend. Notwithstanding the foregoing, (i) if such record date shall have been fixed and such Common Stock Dividend is not fully paid or made on the date fixed therefor, the relevant Conversion Price shall be recomputed accordingly as of the close of business on such record date and thereafter such Conversion Price shall be adjusted pursuant to this Subsection 4. The relevant Conversion Price shall be readjusted in the same manner upon the happening of each subsequent Common Stock Dividend. Please Consider the Environment Before Printing this Document Stock on the date of such event or such record date, as applicable, and had they thereafter, during the period from the date of such event or such record date, as applicable, to and including the conversion date, retained such securities during such period, giving application to all adjustments called for during such period under this Section 4 with respect to the rights of the holders of Preferred Stock or with respect to such other securities by their terms; provided, however, that no such provision shall be made if the holders of Preferred Stock receive, simultaneously with the dividend or distribution to the holders of Common Stock, a dividend or other distribution of such securities, cash or other property in an amount equal to the amount of such securities, cash or other property as they would have received if all outstanding shares of Preferred Stock had been converted into Common Stock on the date of such event or such record date, as applicable. Upon the occurrence of each adjustment or readjustment of any Conversion Price pursuant to this Section 4, the Corporation, at its expense, shall promptly (but in any event not later than ten days thereafter) compute such adjustment or readjustment in accordance with the terms hereof and furnish, or cause to be furnished, to each holder of the relevant series of Preferred Stock a certificate setting forth such adjustment or readjustment (including the kind and amount of securities, cash or other property into which such series of Preferred Stock is convertible) and showing in detail the facts upon which such adjustment or readjustment is based.

The authority vested in this proxy shall run with the Proxy Shares regardless of any change in legal ownership thereof horse with arthritis in back order 200mg celebrex with mastercard. The power of attorney granted by Participant herein is a durable power of attorney and shall survive Participants bankruptcy arthritis bumps 100mg celebrex with visa, death or incapacity. Each party hereto hereby revokes any and all previous proxies and powers of attorney with respect to the Proxy Shares. The representations, warranties, covenants and agreements made in or pursuant to this Agreement shall survive the execution and delivery hereof and shall not be affected by any investigation made by or on behalf of any party hereto. This Agreement, together with the attached Exhibits, sets forth the entire agreement and understanding between the parties hereto relating to the subject matter hereof and supersedes all prior and contemporaneous understandings, agreements, discussions, representations and warranties, both written and oral, between the parties hereto, including any representations made during any interviews or relocation negotiations, with respect to such subject matter. In the event of a conflict between the terms and conditions of the Plan and this Agreement, the terms and conditions of the Plan shall prevail. All notices or other communications required or permitted hereunder shall be in writing and shall be deemed given or delivered (i) when delivered personally, (ii) one business day after being deposited with an overnight courier service (costs prepaid), (iii) when sent by facsimile or e-mail if sent during normal business hours and on the next business day if sent after normal business hours, in each case with confirmation of transmission by the transmitting equipment, or (iv) when received or rejected by the addressee, if sent by certified mail, return receipt requested, postage prepaid, in each case to the addresses, facsimile numbers or e-mail addresses and marked to the attention of the persons designated (by name or title) on the signature page hereto, as applicable, or to such other address, facsimile number, e-mail address or person as such party may designate by a notice delivered to the other party hereto. The Company may assign this Agreement, and its rights and obligations hereunder, in whole or in part, to any successor or assign (whether direct or indirect, by purchase, merger, consolidation, sale of assets or stock or otherwise). Except as set forth herein, (x) neither this Agreement nor any rights, duties and obligations hereunder shall be assigned, transferred, delegated or sublicensed by Participant without the Companys prior written consent and (y) any attempt by Participant to assign, transfer, delegate or sublicense this Agreement or any rights, duties or obligations hereunder, without the Companys prior written consent, shall be void. Subject to any restrictions on transfer set forth herein, this Agreement shall be binding upon, and enforceable against, (i) the Company and its successors and assigns and (ii) Participant and his or her heirs, executors, successors, assigns, administrators and other legal representatives. Except as set forth herein, any transfer in violation of any restriction upon transfer contained in any provision hereof shall be void, unless such restriction is waived in accordance with the terms hereof. This Agreement may not be amended, modified or supplemented except by a written instrument signed by an authorized representative of each party hereto. Any term or provision hereof may be waived, or the time for its performance may be extended, by the party or parties entitled to the benefit thereof. Please Consider the Environment Before Printing this Document is authorized in writing by an authorized representative of such party. The failure or delay of any party to enforce at any time any provision hereof shall not be construed to be a waiver of such provision, nor in any way to affect the validity of this Agreement or any part hereof or the right of any party thereafter to enforce each and every such provision. No waiver of any breach hereof shall be held to constitute a waiver of any other or subsequent breach. Participant shall execute and deliver such additional documents, instruments, conveyances and assurances and take such further actions as may reasonably be necessary or desirable in the view of the Company to carry out the purposes or intent hereof, including the applicable Exhibits attached hereto. Unless the context otherwise requires, references herein: (A) to a Section or an Exhibit mean a Section or an Exhibit of, or attached to , this Agreement; (B) to agreements, instruments and other documents shall be deemed to include all subsequent amendments, supplements and other modifications thereto; (C) to statutes or regulations are to be construed as including all statutory and regulatory provisions consolidating, amending or replacing the statute or regulation referred to; (D) to any Person includes such Persons successors and assigns, but, if applicable, only if such successors and assigns are not prohibited by this Agreement; and (E) to any gender includes each other gender. The titles, captions and headings herein are for convenience of reference only and shall not affect the meaning or interpretation hereof. This Agreement may be executed in counterparts, each of which shall be considered an original, but all of which, when taken together, shall be considered one and the same agreement, and shall become binding when one or more counterparts have been signed by each party hereto and delivered to the other party hereto. Delivery of an executed counterpart of a signature page to this Agreement shall be as effective as delivery of a manually executed counterpart of this Agreement. The exchange of copies of this Agreement and of signature pages hereto by facsimile transmission or e-mail shall constitute effective execution and delivery of this Agreement and may be used in lieu of the original Agreement for all purposes. Signatures transmitted by facsimile or e-mail shall be deemed to be original signatures for all purposes. Please Consider the Environment Before Printing this Document (l) Service Relationship At Will. Participant acknowledges and agrees that the vesting of this Option pursuant hereto is earned only by his or her continuing service as a Service Provider at will (and not through the act of being hired, being granted this Option or acquiring Shares hereunder). Participant further acknowledges and agrees that this Agreement, the transactions contemplated hereby and the vesting schedule set forth herein do not constitute an express or implied promise of continued engagement as a Service Provider for the vesting period, or for any period at all, and shall not interfere with the right of either the Company or Participant to terminate Participants relationship as a Service Provider at any time, with or without cause or notice. In the event of any dividend or other distribution (whether in the form of cash, Shares, other securities or other property), recapitalization, reincorporation, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, reclassification, repurchase or exchange of Shares or other securities of the Company, or other change in the corporate structure of the Company affecting the Shares, the Administrator will appropriately adjust the number, class and price of Shares subject to this Option, with such adjustment to be made in accordance with Section 25102(o) of the California Corporations Code (to the extent the Company is relying upon the exemption afforded thereby with respect thereto) and Section 409A of the Code.

The identification rheumatoid arthritis chemo discount celebrex 100mg online, collection zeel arthritis pain relief purchase 200mg celebrex mastercard, preservation and mode of presentation of physical evidence is known in modern parlance as criminalistics. Criminalistics is the application of sciences such as physics, chemistry, medicine and other biological sciences in crime detection and investigation. Corpus Delicti Evidence - Objects or substances which may be a part of the body of the crime. The body of the victim of murder, prohibited drugs recovered from a person, dagger with blood stains or fingerprints of the suspect, stolen motor vehicle identified by plate number and by body or engine serial numbers are examples of corpus delicti evidence. Associative Evidence - these are physical evidences which link a suspect to the crime. The offender may leave clues at the scene such as weapon, tools, garments, fingerprints or foot impression. Broken headlights glass found at the crime scene in "hit and run" homicide may be associated with the car found in the repair shop. Wearing apparel of the offender and other articles of value may be recovered where the crime of rape was committed. Tracing Evidence -These are physical evidences which may assist the investigator in locating the suspect. Preservation of Evidences: the physical evidences recovered during medico-legal investigation must be preserved to maintain their value when presented as exhibits in court. Most medical evidences are easily destroyed or physically or chemically altered unless appropriate preservation procedure are applied. This problem is further compounded by the long space of time the evidence was recovered and its presentation in court. While in court, the case further suffers delays because of postponement of the hearings, preferential trials of other cases, raising of prejudicial issues to higher courts, etc. Photographs, audio and/or video tape, micro-film, photostat, xerox, voice tracing, etc. Photography is considered to be the most practical, useful and reliable means of preservation. The object preserved is reduced in size in the picture proportionately with other objects adjacent or near it. An unlimited number of copies can be reproduced, each of which is identical to one another. In colored photographs variation may occur in the choice of the kind of film and printing paper used. Audio-recording may be dependent on the speed, volume, pitch and timbre which may be changed by the instrument used in the recording and replaying. Sketching - If no scientific apparatus to preserve evidence is available then a rough drawing of the scene or object to be preserve is done. Rough Sketch - this is made at the crime scene or during examination of living or dead body. On the latter, an anatomic figure of the front, back and side part of the body must be made and the bodily lesions indicated. Finished Sketch - A sketch prepared from the rough sketch for court presentation. Compass direction must always be indicated to facilitate proper orientation in the case of crime scene. There must be a title and legend to tell what it is and the meaning of certain marks indicated therein. Describing a thing requires keen observation and a good power of attention, perception, intelligence and experience. It must cause a vivid impression on the mind of the reader, a true picture of the thing described. The following are the minimum standard requirements which must be satisfied in the description of the person or thing to make it complete: a. Skin Lesion - kind, measurement, other descriptive information of the lesion itself, location, orientation. Penetrating Wound (Punctured, Stab or Gunshot) - kind, shape, other information from the wound itself, location, orientation, direction, other structures involved, complications and foreign elements that may be present. Manikin Method - In a miniature model of a scene or of a human body indicating marks of the various aspects of the things to be preserved. An anatomical model or statuette may be used and injuries are indicated with their appropriate legends.

Buy celebrex 200 mg cheap. Rheumatoid Arthritis new drugs give people hope.

A physician must be cautious concluding that if physical injuries are present arthritis neck pain treatment exercise order celebrex 100mg with amex, they were inflicted in the course of a "third degree" arthritis in neck and jaw cheap celebrex 200mg otc. It could be possible that the subject has self-inflicted those wounds in the guise that the confession was not voluntary. Maltreatment of Prisoners for the Purpose of Exhorting Confession or To Obtain Some Information is a Crime. If the purpose of the maltreatment is to extort a confession, or to obtain some information from the prisoner, the offender shall be punished by prision correccional in its minimum period, temporary special disqualification, and a fine not exceeding 500 pesos, in addition to his liability for the physical injuries or damage caused. The offender has under his charge a (convicted) prisoner or a detention prisoner; 3. By overdoing in the correction or handling of prisoner, either by (1) imposition of punishment not authorized by the regulation, or (2) by inflicting such punishment in a cruel and humiliating manner; or b. By maltreating such prisoner to extort a confession or to obtain some information from the prisoner. The utmost respect for human life is to be maintained even under threat, and no use made of any medical knowledge contrary to the laws of humanity. For the purpose of this Declaration torture is defined as the deliberate, systematic or wanton infliction of physical or mental suffering by one or more persons acting alone or on the orders of any authority, to force another person to yield information, to make a confession, or for any other reason. The doctor shall not provide any premises, instruments, substances or knowledge to facilitate the practice of torture or other forms of cruel, inhuman or degrading treatment or to diminish the ability of the victim to resist such treatment. The doctor shall not be present during any procedure during which torture or other forms of cruel, inhuman or degrading treatment is used or threatened. A doctor must have complete clinical independence in deciding upon the care for a person for whom he or she is medically responsible. Where a prisoner refuses nourishment and is considered by the doctor as capable of forming an unimpaired and rational judgment concerning the consequences of such voluntary refusal of nourishment, he or she shall not be fed artificially. The decision as to the capacity of the prisoner to form such a judgement should be confirmed by at least one other independent doctor. The consequences of the refusal of nourishment shall be explained by the doctor to the prisoner. It is conclusive upon the court and may be considered to be a mitigating circumstance to criminal liability. A plea of guilty when formally entered on arraignment is sufficient to sustain a conviction of any offense, even a capital one, without further proof. In the prosecution of the criminal offense, the identity of the offender and that of the victim must be established, otherwise it will be a ground for the dismissal of the charge or acquital of the accused. The identification of a person missing or presumed dead will facilitate settlement of the estate, retirement, insurance and other social benefits. Identification resolves the anxiety of the next-of-kin, other relatives and friends as to the whereabouts of a missing person or victim of calamity or criminal act. Identification may be needed in some transactions, like cashing of check, entering a premise, delivery of parcels or registered mail in post office, sale of property, release of dead bodies to relatives, parties to a contract, etc. The greater the number of points of similarities and dissimilarities of two persons compared, the greater is the probability for the conclusion to be correct. The value of the different points of identification varies in the formulation of conclusion. In a fresh cadaver, if the fingerprints on file are the same as those recovered from the crime scene, they will positively establish the identity of the person while bodily marks, like moles, scars, complexion, shape of nose, etc. Visual recognition by relative or friends may be of lesser value as compared with fingerprints or dental comparison. The longer the interval between the death and the examination of the remains for purposes of identification, the greater is the need for experts in establishing identity. The process of taking fingerprints and its examination under a magnifying lens requires the services of an expert. Inasmuch as the object to be identified is highly perishable, it is necessary for the team to act in the shortest possible time specially in cases of mass disaster. There is no rigid rule to be observed in the procedure of identification of persons. By comparison - Identification criteria recovered during investigation are compared with records available in the file, or postmortem finding are compared with ante-mortem records. Latent fingerprints recovered from the crime scene are compared with the fingerprints on file of an investigating agency.

The terms of these types of agreements may include (i) licenses to the Companys technology arthritis relief miracle buy 100 mg celebrex free shipping, (ii) research and development services arthritis neck inflammation 200 mg celebrex overnight delivery, and (iii) services or obligations in connection with participation in research or steering committees. Please Consider the Environment Before Printing this Document Table of Contents as well as royalties on sales of any commercialized products. Arrangements that include upfront payments are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until performance obligations are met. The event-based milestone payments, royalties and cost reimbursements represent variable consideration, and the Company uses the most likely amount method to estimate this variable consideration. The Company records cost reimbursements as accounts receivable when right to consideration is unconditional. The Company allocates the total transaction price to each performance obligation based on the estimated relative to standalone selling price and recognizes revenue when, or as, the performance obligation is satisfied. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. At the end of each reporting period, the Company reevaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. When upfront payments were received and if there was no discernible pattern of performance, the Company recognized revenue ratably over the associated period of performance. Research and Development Expenses Costs related to research, design and development of programs are charged to research and development expense as incurred. Research and development costs include, but are not limited to , payroll and personnel expenses including stock-based compensation, materials, laboratory supplies, outside services and allocated overhead, including rent, insurance, repairs and maintenance, depreciation and utilities. The Company expenses all research and development costs in the period in which they are incurred. Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use. The Companys research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued and other current liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Stock-Based Compensation the Company accounts for stock-based compensation as measured at grant date, based on the fair value of the award. The Company measures the fair value of awards granted using the Black-Scholes option pricing model and recognizes the expense in the Companys Statements of Operations and Comprehensive Loss over the requisite service period using the straight-line method. The Companys policy for issuing stock upon stock option exercise is to issue new common stock. The Company recognizes the fair value of stock options granted to nonemployees as stock-based compensation expense over the period in which the related services are received. Stock-based compensation expense related to stock options granted to nonemployees is recognized based on the vesting date fair value of awards as the stock options are earned. The Company believes that the estimated fair value of stock options is more readily measurable than the fair value of the services rendered. In addition, the Company estimates the service period for the awards based on the time that would be required to satisfy the service condition, assuming the service condition will be satisfied. Stock-based compensation expense is recognized over the estimated service period but is accelerated if the performance condition is achieved earlier than estimated. Income Taxes the Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Companys assets and liabilities and their financial statement reported amounts. A valuation allowance is provided against deferred tax assets unless it is more likely than not that they will be realized. The Company accounts for uncertain tax positions by assessing all material positions taken in any assessment or challenge by relevant taxing authorities. The Companys policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. Embedded Derivative Embedded derivatives that are required to be bifurcated from the underlying host instrument are accounted for and valued as a separate financial instrument.

References:

• https://www.osha.gov/sites/default/files/publications/OSHA3767.pdf
• https://www.roslynschools.org/site/handlers/filedownload.ashx?moduleinstanceid=1193&dataid=1182&FileName=Disorder_Detectives_Lab.pdf
• http://cmm.ucsd.edu/cleveland/DWC%20Journal%20PDF%20files/2008/Vande%20Velde%20and%20Cleveland%20(2008)%20Encyc.%20of%20Neurosci.%201,%20369-373,%20Academic%20Press%20(Oxford).pdf